Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
暂无分享,去创建一个
Gavin Thurston | Hsin C. Lin | Nicholas W. Gale | G. Yancopoulos | N. Papadopoulos | N. Gale | G. Thurston | Christopher Daly | George D. Yancopoulos | P. Boland | I. Noguera-Troise | C. Daly | S. Coetzee | Irene Noguera-Troise | Sandra Coetzee | Pat Boland | Hsin Chieh Lin | Nicholas J. Papadopoulos | Sandra Coetzee | H. Lin | Irene Noguera-Troise
[1] J. Hsieh,et al. A secreted Delta1‐Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling , 2002, Journal of neuroscience research.
[2] J. Kitajewski,et al. Notch function in the vasculature: insights from zebrafish, mouse and man , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.
[3] Peter Carmeliet,et al. Angiogenesis in life, disease and medicine , 2005, Nature.
[4] Tasuku Honjo,et al. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. , 2004, Genes & development.
[5] Janet Rossant,et al. Dosage-sensitive requirement for mouse Dll4 in artery development. , 2004, Genes & development.
[6] Christopher C W Hughes,et al. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. , 2002, Microvascular research.
[7] T. Gridley. Notch signaling during vascular development , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] H. Augustin,et al. Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. , 2006, Cancer research.
[9] R. Kerbel,et al. Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches , 2004, Cancer and Metastasis Reviews.
[10] M. Herlyn,et al. Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1 , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[11] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[12] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[13] R Bicknell,et al. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. , 2001, Differentiation; research in biological diversity.
[14] J. Folkman,et al. The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.
[15] D. McDonald,et al. Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. , 1996, The American journal of physiology.
[16] Jeffrey W. Clark,et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.
[17] G. Yancopoulos,et al. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets. , 2005, Cold Spring Harbor symposia on quantitative biology.
[18] M. Bevan,et al. The Nrarp gene encodes an ankyrin-repeat protein that is transcriptionally regulated by the notch signaling pathway. , 2001, Developmental biology.
[19] S. Artavanis-Tsakonas,et al. Notch signaling: cell fate control and signal integration in development. , 1999, Science.
[20] Stanley J. Wiegand,et al. Vascular-specific growth factors and blood vessel formation , 2000, Nature.
[21] Larry Kedes,et al. HES and HERP families: Multiple effectors of the notch signaling pathway , 2003, Journal of cellular physiology.
[22] A. Karsan. The role of notch in modeling and maintaining the vasculature. , 2005, Canadian journal of physiology and pharmacology.
[23] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[24] M Ancukiewicz,et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.
[25] Oriol Casanovas,et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.
[26] Gavin Thurston,et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] C. Niehrs,et al. Nrarp is a novel intracellular component of the Notch signaling pathway. , 2001, Genes & development.
[28] A. Sandler,et al. First-line treatment for advanced non-small-cell lung cancer. , 2005, Oncology.
[29] Rakesh K Jain,et al. Antiangiogenic therapy for cancer: current and emerging concepts. , 2005, Oncology.
[30] R. Jain. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. , 2002, Seminars in oncology.
[31] Adrian L Harris,et al. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. , 2005, Cancer research.
[32] N. Ferrara. Vascular endothelial growth factor as a target for anticancer therapy. , 2004, The oncologist.
[33] J. Kitajewski,et al. Notch Signaling in Primary Endothelial Cells , 2003, Annals of the New York Academy of Sciences.